Generation of circulating tumor cell derived organoids through enrichment by leukapheresis - A novel drug screening system in metastatic prostate cancer
Recruiting
- Conditions
- prostate cancerprostate carcinoma10038364
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 79
Inclusion Criteria
- metastasized prostate cancer
- age * 18 years
- Written informed consent of the patient
- * 2 adequate peripheral veins as access point for leukapheresis
Exclusion Criteria
- CTC count of < 5 CTCs/7.5 mL of blood
- Patients with a known hypersensitivity to the used LA-anticoagulant
- mHSPC patients with current ADT
- Hemorrhage disease and/or coagulation disorder
- Inadequate liver and/or renal function
- Inadequate hematology and coagulation status
- Chronic viral infections
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary endpoint is the success rate of culturing organoids from CTCs<br /><br>obtained by LA. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary endpoints include the fraction of metastatic PCa patients who have *<br /><br>300 viable CTCs obtained by LA and the exploratory analysis comparing drug<br /><br>sensitivity in organoids to therapy response of the matching patient in the<br /><br>clinic.</p><br>